SEMA4D and breast carcinoma: As shown in Figure 1, our IHC results demonstrated that SEMA4D was expressed at significantly higher levels in multiple cancer types, including liver cancer, endometrial cancer, colon cancer, breast cancer, skin melanoma, lung cancer, renal cancer, testicular cancer, ovarian cancer, lymphoma, head-neck squamous cell carcinoma, pancreatic cancer, and glioma, compared to the respective normal tissues (n=3).